Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.

Receptor tyrosine kinases (RTKs), in response to their growth factor ligands, phosphorylate and activate downstream signals important for physiological development and pathological transformation. Increased expression, activating mutations and rearrangement fusions of RTKs lead to cancer, inflammati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ramesh Narayanan, Muralimohan Yepuru, Christopher C Coss, Zhongzhi Wu, Matthew N Bauler, Christina M Barrett, Michael L Mohler, Yun Wang, Juhyun Kim, Linda M Snyder, Yali He, Nelson Levy, Duane D Miller, James T Dalton
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/99a4bb75c3cc4be7b28f17e6807eb989
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!